This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Align Technology (ALGN) Q2 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Strength in Invisalign Clear Aligners and iTero scanners sales volumes during the fiscal second quarter drove Align Technology's (ALGN) top line.
Align Technology (ALGN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Align Technology (ALGN) delivered earnings and revenue surprises of 20.63% and 7.27%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific (BSX) Q2 Earnings Beat, 2021 Guidance Up
by Zacks Equity Research
Organic revenues at each of Boston Scientific's (BSX) core business segments and geographies increase in Q2.
Medical Device Stocks' Earnings on Jul 28: TMO, ALGN & More
by Urmimala Biswas
The sector's Q2 results are likely to reflect solid earnings and revenue growth on strong base business recovery.
Overstock.com (OSTK) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Overstock.com's (OSTK) Q2 results are expected to reflect strength in expanding clientele and demand for online home furnishing. Stiff competition and cost escalations are overhangs.
Why Align Technology (ALGN) Might Surprise This Earnings Season
by Zacks Equity Research
Align Technology (ALGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
The Zacks Analyst Blog Highlights: Align Technology and Shopify
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Align Technology and Shopify
Why Align Technology (ALGN) Could Beat Earnings Estimates Again
by Zacks Equity Research
Align Technology (ALGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Quest Diagnostics (DGX) Q2 Earnings Beat, Base Testing Strong
by Zacks Equity Research
According to Quest Diagnostics (DGX), Q2 is the first quarter since 2019 in which it has registered organic base testing revenue growth.
Abbott (ABT) Q2 Earnings Beat, Molecular Diagnostic Sales Drop
by Zacks Equity Research
Abbott's (ABT) Adult Nutrition sales benefit from improved sales performance of complete and balanced nutrition brand Ensure and diabetes nutrition brand, Glucerna in Q2.
Align Technology (ALGN) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Continued adoption of Invisalign Clear Aligners and iTero scanners are expected to have contributed to the Align Technology's (ALGN) second-quarter 2021 results.
Buy These 2 Growth Stocks Before Earnings and Hold for Years?
by Benjamin Rains
Here are two strong growth-focused stocks poised to thrive for years that investors might want to consider buying around their Q2 earnings reports...
Align Technology (ALGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Align Technology (ALGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nevro's (NVRO) Senza System Approved by FDA for PDN Treatment
by Zacks Equity Research
Nevro's (NVRO) 10 kHz SCS treatment, which has received the FDA nod for treating patients with PDN, is expected to provide sustained pain relief as well as improve health-related quality of life.
Nevro (NVRO) Reports Impressive Preliminary Q2 Revenues
by Zacks Equity Research
Improvement in Nevro's (NVRO) second-quarter revenues is likely to have resulted from a solid product portfolio.
Neogen (NEOG) Misses Q4 Earnings, Tops Revenue Estimates
by Zacks Equity Research
Strong segmental revenues and solid international performance across Neogen's (NEOG) entire business drove its topline.
Intuitive Surgical (ISRG) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results reflect strong segmental performance.
Masimo (MASI) Boosts Its Product Suite With Latest Release
by Zacks Equity Research
Masimo's (MASI) latest offering is expected to improve patient care due to its re-engineered integration design.
Cerner (CERN) Extends Partnership to Accelerate Digital Health
by Zacks Equity Research
Cerner (CERN) expands its partnership with Baystate Health by launching a digital health platform to boost consumer-focused care.
Reasons to Add Veeva Systems (VEEV) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.
Catalent (CTLT) Inks Deal for Feasibility Study of CBD Product
by Zacks Equity Research
Catalent's (CTLT) latest agreement is expected to lead to a prototype development of a Zydis formulation via a feasibility study.
3 Stocks to Tap the Promising Dental Supplies Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical-Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
AngioDynamics (ANGO) Q4 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth across all its GBUs in fiscal 2021 Q4.
Stryker (SYK) Unveils Tornier Shoulder Arthroplasty Portfolio
by Zacks Equity Research
Stryker (SYK) introduces new Tornier shoulder arthroplasty portfolio enabling the company to strengthen its position in the shoulder market.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from robust payment accuracy business. However, intense competition remains a woe.